α-1-酸性糖蛋白的糖基化变化作为肝细胞癌和肝硬化的血清生物标志物。
Glycosylation change of alpha-1-acid glycoprotein as a serum biomarker for hepatocellular carcinoma and cirrhosis.
机构信息
Department of Hepatobiliary Surgery, Guizhou Provincial People's Hospital, Guiyang, China.
出版信息
Biomark Med. 2017 May;11(5):423-430. doi: 10.2217/bmm-2016-0284.
AIM
This research is to explore the glycosylation change of alpha-1-acid glycoprotein (AGP) in hepatocellular carcinoma (HCC), cirrhosis and controls.
METHODS
The affinity chromatography and lectin affinity techniques were used to separate and enrich glycosylated AGP, and combined with mass spectrometry to identify and relatively quantify the glycopeptides from AGP.
RESULTS
The sialylation and fucosylation of AGP were different among HCC, cirrhosis and controls. The highly sialylated and fucosylated peptides from AGP were found in HCC and cirrhosis compared with controls. These glycopeptides showed excellent diagnostic ability to differentiate HCC from cirrhosis (area under the curve >0.9). In addition, these glycopeptides showed significantly different among four HCC stages.
CONCLUSION
The sialylation and fucosylation change of AGP may serve as serum biomarker for HCC and cirrhosis.
目的
本研究旨在探讨α-1-酸性糖蛋白（AGP）在肝细胞癌（HCC）、肝硬化和对照组中的糖基化变化。
方法
采用亲和层析和凝集素亲和技术分离和富集糖基化 AGP，并结合质谱技术对 AGP 的糖肽进行鉴定和相对定量。
结果
HCC、肝硬化和对照组的 AGP 的唾液酸化和岩藻糖化程度不同。与对照组相比，HCC 和肝硬化患者的 AGP 中存在高度唾液酸化和岩藻糖化的肽段。这些糖肽对区分 HCC 和肝硬化具有极好的诊断能力（曲线下面积>0.9）。此外，这些糖肽在四个 HCC 阶段之间存在显著差异。
结论
AGP 的唾液酸化和岩藻糖化变化可能可作为 HCC 和肝硬化的血清生物标志物。
Zotero 插件